To test this hypothesis, MC38 tumor-bearing mice were depleted of CD4+ T cells by injecting an anti-CD4 antibody followed by Bpmel-OVAI-Ea cell adjuvant therapy (Fig. 3, A and B). This evidence concerns the gene CD4 and neoplasm.